CHIT1 and early-onset autosomal dominant Alzheimer disease: In addition, as shown in Alzheimer’s disease clinical trials targeting neuroinflammation [80], chitotriosidase and perhaps MCP-1 could serve as pharmacodynamic markers of neuroinflammation, specifically microglial activation, which would be relevant for use in cerebral ALD clinical trials.